Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Accuracy of diagnostic codes for prenatal opioid exposure and neonatal opioid withdrawal syndrome

Journal of Perinatology volume 43, pages 293–299 (2023)Cite this article

Subjects

Abstract

Objective

Determine the accuracy of diagnostic codes in identifying Prenatal Opioid Exposure (POE) and Neonatal Opioid Withdrawal Syndrome (NOWS).

Study design

A cross-sectional study of 374,222 mother-infant dyads with delivery from 01/01/2010 to 12/31/2019. We ascertained maternal diagnostic codes for opioid use during pregnancy and infant diagnostic codes for drug exposure and withdrawal. We assessed sensitivity and positive predictive value (PPV) for POE and NOWS, defined using laboratory, pharmacy, and clinical data.

Results

Maternal codes had low sensitivity (36.4%) and PPV (34.7%) for POE. Infant codes for drug exposure were neither sensitive for POE (14%) nor NOWS (31.6%) and had low PPV. Codes for newborn withdrawal had low sensitivity (31.6%) for detecting NOWS, but high PPV (85%). Sensitivity improved (95.1%) for NOWS requiring pharmacologic treatment.

Conclusions

Diagnostic codes identify POE and NOWS poorly. Improved case identification would include pharmacy and laboratory results, and clearly defined criteria for evidence of withdrawal.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Code availability

All analyses were performed using SAS version 9.4. The code used is available upon request.

Data availability

The datasets generated for this study are stored at the KPNC Division of Research. Deidentified data can be provided upon reasonable request to the corresponding author, and with permission from the KPNC Institutional Review Board.

References

  1. Summers AD, Ailes EC, Bohm MK, Tran EL, Broussard CS, Frey MT, et al. Opioid prescription claims among women aged 15-44 years-United States, 2013–2017. J Opioid Manag. 2021;17:125–33.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Hirai AH, Ko JY, Owens PL, Stocks C, Patrick SW. Neonatal abstinence syndrome and maternal opioid-related diagnoses in the US, 2010–2017. JAMA. 2021;325:146–55.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Honein MA, Boyle C, Redfield RR. Public health surveillance of prenatal opioid exposure in mothers and infants. Pediatrics. 2019;143:3.

  4. Prevention CfDCa. Public health grand rounds: surveillance for emerging threats to pregnant women and infants: data for action Atlanta, GA2018 [Available from: https://www.cdc.gov/grand-rounds/pp/2018/20180918-pregnancy-threats.html.

  5. Chiang KV, Okoroh EM, Kasehagen LJ, Garcia-Saavedra LF, Ko JY. Standardization of state definitions for neonatal abstinence syndrome surveillance and the opioid crisis. Am J Public Health. 2019;109:1193–7.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Jilani SM, Frey MT, Pepin D, Jewell T, Jordan M, Miller AM, et al. Evaluation of state-mandated reporting of neonatal abstinence syndrome - six states, 2013–2017. MMWR Morb Mortal Wkly Rep. 2019;68:6–10.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Phillips-Bell GS, Holicky A, Lind JN, Sappenfield WM, Hudak ML, Petersen E, et al. Assessing the burden of neonatal abstinence syndrome: validation of ICD-9-CM data, Florida, 2010–2011. J Public Health Manag Pr. 2020;26:E1–E8.

    Google Scholar 

  8. Elmore AL, Tanner JP, Lowry J, Lake-Burger H, Kirby RS, Hudak ML, et al. Diagnosis codes and case definitions for neonatal abstinence syndrome. Pediatrics. 2020;146:6.

  9. Epidemiologists CoSaT. Council of State and Territorial Epidemiologists Neonatal Abstinence Syndrome Standardized Case Definition Atlanta, GA2019 [Available from: https://cdn.ymaws.com/www.cste.org/resource/resmgr/2019ps/final/19-MCH-01_final_7.31.19.pdf.

  10. Gordon N. Similarity of the adult Kaiser Permanente membership in Northern California to the insured and general population in Northern California: Statistics from the 2011-12 California Health Interview Survey. 2015.

  11. Chimmula S, Dhuru R, Folck B, Gul J, Lee M, Ng D, et al. PS2-44: VDW data sources: Kaiser Permanente Northern California. Clin Med Res. 2012;10:193.

    Article  PubMed Central  Google Scholar 

  12. Selby JV, Smith DH, Johnson ES, Raebel MA, Friedman GD, McFarland BH. Kaiser permanente medical care program. In: Strom BL, editor. Pharmacoepidemiology. 4 ed. New York: Wiley; 2005. p. 241–59.

  13. Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis. 1975;2:141–58.

    CAS  PubMed  Google Scholar 

  14. Jones HE, Harrow C, O’Grady KE, Crocetti M, Jansson LM, Kaltenbach K. Neonatal abstinence scores in opioid-exposed and nonexposed neonates: a blinded comparison. J Opioid Manag. 2010;6:409–13.

    Article  PubMed  Google Scholar 

  15. Jilani SM, Jones HE, Davis JM. Implementation of a standardized clinical definition of opioid withdrawal in the neonate: challenges and opportunities. JAMA. 2022;327:1643–4.

    Article  PubMed  Google Scholar 

  16. Kuzniewicz MW, Escobar GJ, Newman TB. Impact of universal bilirubin screening on severe hyperbilirubinemia and phototherapy use. Pediatrics. 2009;124:1031–9.

    Article  PubMed  Google Scholar 

  17. MacVicar S, Kelly LE. Systematic mixed-study review of nonpharmacological management of neonatal abstinence syndrome. Birth. 2019;46:428–38.

    Article  PubMed  Google Scholar 

  18. Grossman MR, Lipshaw MJ, Osborn RR, Berkwitt AK. A novel approach to assessing infants with neonatal abstinence syndrome. Hosp Pediatr. 2018;8:1–6.

    Article  PubMed  Google Scholar 

  19. Grossman MR, Berkwitt AK, Osborn RR, Xu Y, Esserman DA, Shapiro ED, et al. An initiative to improve the quality of care of infants with neonatal abstinence syndrome. Pediatrics. 2017;139:e1–e8.

  20. Camden A, Ray JG, To T, Gomes T, Bai L, Guttmann A. Identification of prenatal opioid exposure within health administrative databases. Pediatrics. 2021;147:1–9.

  21. Doherty KM, Scott TA, Morad A, Crook T, McNeer E, Lovell KS, et al. Evaluating definitions for neonatal abstinence syndrome. Pediatrics. 2021;147:1–6.

  22. Goyal S, Saunders KC, Moore CS, Fillo KT, Ko JY, Manning SE, et al. Identification of substance-exposed newborns and neonatal abstinence syndrome using ICD-10-CM - 15 hospitals, Massachusetts, 2017. MMWR Morb Mortal Wkly Rep. 2020;69:951–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Maalouf FI, Cooper WO, Stratton SM, Dudley JA, Ko J, Banerji A, et al. Positive predictive value of administrative data for neonatal abstinence syndrome. Pediatrics. 2019;143:1–6.

  24. Patrick SW, Dudley J, Martin PR, Harrell FE, Warren MD, Hartmann KE, et al. Prescription opioid epidemic and infant outcomes. Pediatrics. 2015;135:842–50.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Sujan AC, Quinn PD, Rickert ME, Wiggs KK, Lichtenstein P, Larsson H, et al. Maternal prescribed opioid analgesic use during pregnancy and associations with adverse birth outcomes: A population-based study. PLoS Med. 2019;16:e1002980.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Brogly SB, Velez MP, Werler MM, Li W, Camden A, Guttmann A. Prenatal opioid analgesics and the risk of adverse birth outcomes. Epidemiology. 2021;32:448–56.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Falk J, Dahl M, Raymond CB, Chateau D, Katz A, Leong C, et al. Opioid use during pregnancy: a population-based cohort study. CMAJ Open. 2017;5:E517–23.

    Article  PubMed  PubMed Central  Google Scholar 

  28. D’Apolito KC. Assessing neonates for neonatal abstinence: are you reliable? J Perinat Neonatal Nurs. 2014;28:220–31.

    Article  Google Scholar 

  29. Hudak ML, Tan RC, Committee On D, Committee On F, Newborn, American Academy of P. Neonatal drug withdrawal. Pediatrics. 2012;129:e540–60.

    Article  PubMed  Google Scholar 

  30. Jones HE, Seashore C, Johnson E, Horton E, O’Grady KE, Andringa K, et al. Psychometric assessment of the neonatal abstinence scoring system and the MOTHER NAS scale. Am J Addict. 2016;25:370–3.

    Article  PubMed  Google Scholar 

Download references

Funding

This project was supported by FDA Contract 75F40119C10101. CIC receives funds through her institution from the Opioid Postmarketing Requirements (PMR) Consortium for research on risks of long-term prescription opioid use, conducted as part of a Food and Drug Administration postmarketing requirement for extended-release and long-acting opioid analgesics. The remaining authors have no financial relationships relevant to this article to disclose.

Author information

Authors and Affiliations

  1. Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA

    Michael W. Kuzniewicz, Cynthia I. Campbell, Sherian Li, Eileen M. Walsh, Lisa A. Croen & Monique Hedderson

  2. Department of Pediatrics, University of California, San Francisco, CA, USA

    Michael W. Kuzniewicz

  3. Department of Pediatrics, Kaiser Permanente Northern California, Oakland, CA, USA

    Michael W. Kuzniewicz

  4. Department of Psychiatry, Columbia University, New York, NY, USA

    Sandra D. Comer

  5. Department of Statistics, University of California, Berkeley, CA, USA

    Samuel D. Pimentel

  6. Department of Anesthesiology and Pediatrics, Columbia University, New York, NY, USA

    Lena S. Sun

Authors
  1. Michael W. Kuzniewicz
    View author publications

    Search author on:PubMed Google Scholar

  2. Cynthia I. Campbell
    View author publications

    Search author on:PubMed Google Scholar

  3. Sherian Li
    View author publications

    Search author on:PubMed Google Scholar

  4. Eileen M. Walsh
    View author publications

    Search author on:PubMed Google Scholar

  5. Lisa A. Croen
    View author publications

    Search author on:PubMed Google Scholar

  6. Sandra D. Comer
    View author publications

    Search author on:PubMed Google Scholar

  7. Samuel D. Pimentel
    View author publications

    Search author on:PubMed Google Scholar

  8. Monique Hedderson
    View author publications

    Search author on:PubMed Google Scholar

  9. Lena S. Sun
    View author publications

    Search author on:PubMed Google Scholar

Contributions

MWK conceptualized and designed the study, obtained funding, acquired the data, carried out all data analysis, drafted the initial manuscript, and reviewed and revised the manuscript. CIC, SDC, LAC, SDP, and MH assisted in interpreting the analyses, assisted in writing the initial draft, and reviewed and revised the manuscript. SL was responsible for acquiring the data, building the datasets, and reviewing and revising the manuscript. EMW reviewed the data, performed chart review for data accuracy when needed, and reviewed and revised the manuscript. LSS assisted in the conceptualization and design of the study, obtained funding, reviewed data analyses, assisted in writing the initial draft and reviewed and revised the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Corresponding author

Correspondence to Eileen M. Walsh.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

The study was reviewed and approved by the following boards. Individual consent of subjects was waived. Kaiser Permanente Northern California Institutional Review Board (#1507334). California Committee for the Protection of Human Subjects (#2021-043). The study is in accordance with the Declaration of Helsinki.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kuzniewicz, M.W., Campbell, C.I., Li, S. et al. Accuracy of diagnostic codes for prenatal opioid exposure and neonatal opioid withdrawal syndrome. J Perinatol 43, 293–299 (2023). https://doi.org/10.1038/s41372-022-01518-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41372-022-01518-y

Search

Advanced search

Quick links